Related Experiment Video

Updated: Jun 1, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Novel chemotherapy using histone deacetylase inhibitors in cervical cancer

Noriyuki Takai1, Naoko Kira, Terukazu Ishii

  • 1Department of Obstetrics and Gynecology, Oita University Faculty of Medicine, Oita, Japan. takai@oita-u.ac.jp

Asian Pacific Journal of Cancer Prevention : APJCP
|June 2, 2011
PubMed

Insights

Histone deacetylase inhibitors (HDACIs) show promise in cervical cancer treatment by inhibiting tumor growth and promoting apoptosis. Preclinical and clinical studies highlight their potential as novel, mechanism-based therapeutics with manageable side effects.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • Epigenetic alterations, including histone deacetylase (HDAC) activity, are implicated in cervical cancer development by repressing tumor suppressor genes.
  • Histone deacetylase inhibitors (HDACIs) represent a promising therapeutic strategy targeting these epigenetic modifications.

Purpose of the Study:

  • To review the biological and therapeutic effects of HDAC inhibitors in cervical cancer treatment.
  • To focus on preclinical studies and clinical trials evaluating HDACIs for cervical cancer.

Main Methods:

  • Review of existing literature on HDAC inhibitors in cervical cancer.
  • Analysis of preclinical data from cell lines and xenograft models.
  • Evaluation of outcomes from clinical trials of HDACIs in cervical cancer patients.

Main Results:

  • HDACIs demonstrated inhibition of cell growth, cell cycle arrest, and apoptosis in cervical cancer cell lines.
  • HDACIs induced histone acetylation at the p21WAF1 gene in human cervical carcinoma cells.
  • Antitumor activity with minimal side effects was observed in xenograft models; clinical trials support HDACIs as a new therapeutic class.

Conclusions:

  • HDAC inhibitors exhibit significant preclinical efficacy and clinical potential for cervical cancer treatment.
  • HDACIs offer a novel mechanism-based therapeutic approach for managing cervical cancer.
  • Further clinical investigation is warranted to fully establish the role of HDACIs in cervical cancer therapy.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3 variants are also...